Appointment dossier — Clear Cell Carcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Clear Cell Carcinoma
No studies or cited compounds on file for this cancer yet.
Open recruiting trials (18)
- NCT07072234 · Phase 1 — Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma (United States)
- NCT05663710 · Phase 1 / Phase 2 — Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC (United States)
- NCT05706129 · Phase 1 / Phase 2 — A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors (Australia)
- NCT06638931 · Phase 2 — Agnostic Therapy in Rare Solid Tumors (Brazil)
- NCT06270706 · Phase 1 — A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors (United States)
- NCT05238922 · Phase 1 — Study of INCB123667 in Subjects With Advanced Solid Tumors (United States)
- NCT06026410 · Phase 1 — KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (United States)
- NCT06349642 — Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform (United States)
- NCT06750419 · Phase 3 — 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study (China)
- NCT06835972 · Phase 1 / Phase 2 — A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC) (United States)
- NCT06680089 · Phase 2 — CD70-targeted immunoPET Imaging of Kidney Cancer (China)
- NCT06866262 · Phase 1 / Phase 2 — Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial (United States)
- NCT06699602 · Phase 2 — A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma (United States)
- NCT07223541 · Phase 2 — Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma (United States)
- NCT06239272 · Phase 1 / Phase 2 — NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) (United States)
- NCT07386158 · Phase 2 — Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC (China)
- NCT04919629 · Phase 2 — APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion (United States)
- NCT05231122 · Phase 2 — Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer (United States)
Most-relevant first: trials that name Clear Cell Carcinoma, then broader trials you may still qualify for. 123 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
Questions to ask your oncologist
- Of the open trials I found (for example NCT07072234), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?